Literature DB >> 25913133

Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Shreya Raghavan1, Maria R Ward1, Katelyn R Rowley2, Rachel M Wold2, Shuichi Takayama3, Ronald J Buckanovich4, Geeta Mehta5.   

Abstract

BACKGROUND: Ovarian cancer grows and metastasizes from multicellular spheroidal aggregates within the ascites fluid. Multicellular tumor spheroids are therefore physiologically significant 3D in vitro models for ovarian cancer research. Conventional hanging drop cultures require high starting cell numbers, and are tedious for long-term maintenance. In this study, we generate stable, uniform multicellular spheroids using very small number of ovarian cancer cells in a novel 384 well hanging drop array platform.
METHODS: We used novel tumor spheroid platform and two ovarian cancer cell lines (A2780 and OVCAR3) to demonstrate the stable incorporation of as few as 10 cells into a single spheroid.
RESULTS: Spheroids had uniform geometry, with projected areas (42.60×10(3)μm-475.22×10(3)μm(2) for A2780 spheroids and 37.24×10(3)μm(2)-281.01×10(3)μm(2) for OVCAR3 spheroids) that varied as a function of the initial cell seeding density. Phalloidin and nuclear stains indicated cells formed tightly packed spheroids with demarcated boundaries and cell-cell interaction within spheroids. Cells within spheroids demonstrated over 85% viability. 3D tumor spheroids demonstrated greater resistance (70-80% viability) to cisplatin chemotherapy compared to 2D cultures (30-50% viability).
CONCLUSIONS: Ovarian cancer spheroids can be generated from limited cell numbers in high throughput 384 well plates with high viability. Spheroids demonstrate therapeutic resistance relative to cells in traditional 2D culture. Stable incorporation of low cell numbers is advantageous when translating this research to rare patient-derived cells. This system can be used to understand ovarian cancer spheroid biology, as well as carry out preclinical drug sensitivity assays.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D culture; High throughput; Multicellular tumor spheroids; Ovarian cancer; Preclinical drug testing

Mesh:

Year:  2015        PMID: 25913133      PMCID: PMC4480341          DOI: 10.1016/j.ygyno.2015.04.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  42 in total

1.  Media additives to promote spheroid circularity and compactness in hanging drop platform.

Authors:  Brendan M Leung; Sasha Cai Lesher-Perez; Toshiki Matsuoka; Christopher Moraes; Shuichi Takayama
Journal:  Biomater Sci       Date:  2014-11-13       Impact factor: 6.843

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 3.  Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Authors:  Daniela Luvero; Andrea Milani; Jonathan A Ledermann
Journal:  Ther Adv Med Oncol       Date:  2014-09       Impact factor: 8.168

4.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

5.  High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array.

Authors:  Yi-Chung Tung; Amy Y Hsiao; Steven G Allen; Yu-suke Torisawa; Mitchell Ho; Shuichi Takayama
Journal:  Analyst       Date:  2010-10-21       Impact factor: 4.616

Review 6.  The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.

Authors:  Leoni A Kunz-Schughart; James P Freyer; Ferdinand Hofstaedter; Reinhard Ebner
Journal:  J Biomol Screen       Date:  2004-06

Review 7.  Multicellular tumor spheroids: an underestimated tool is catching up again.

Authors:  Franziska Hirschhaeuser; Heike Menne; Claudia Dittfeld; Jonathan West; Wolfgang Mueller-Klieser; Leoni A Kunz-Schughart
Journal:  J Biotechnol       Date:  2010-01-25       Impact factor: 3.307

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 9.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

Review 10.  Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment.

Authors:  David Herrmann; James R W Conway; Claire Vennin; Astrid Magenau; William E Hughes; Jennifer P Morton; Paul Timpson
Journal:  Carcinogenesis       Date:  2014-06-05       Impact factor: 4.944

View more
  47 in total

1.  Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.

Authors:  Hong Song; Guo-Hui Cai; Jian Liang; Di-Shu Ao; Huan Wang; Ze-Hong Yang
Journal:  J Nanobiotechnology       Date:  2020-06-11       Impact factor: 10.435

2.  Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.

Authors:  Jason R Brown; Daniel K Chan; Jessica J Shank; Kent A Griffith; Huihui Fan; Robert Szulawski; Kun Yang; R Kevin Reynolds; Carolyn Johnston; Karen McLean; Shitanshu Uppal; J Rebecca Liu; Lourdes Cabrera; Sarah E Taylor; Brian C Orr; Francesmary Modugno; Pooja Mehta; Michael Bregenzer; Geeta Mehta; Hui Shen; Lan G Coffman; Ronald J Buckanovich
Journal:  JCI Insight       Date:  2020-06-04

Review 3.  Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.

Authors:  Zehong Yang; Hongyan Xu; Xiaojun Zhao
Journal:  Adv Sci (Weinh)       Date:  2020-03-20       Impact factor: 16.806

4.  Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.

Authors:  Shreya Raghavan; Pooja Mehta; Maria R Ward; Michael E Bregenzer; Elyse M A Fleck; Lijun Tan; Karen McLean; Ronald J Buckanovich; Geeta Mehta
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

5.  UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells.

Authors:  Ashley Mooneyham; Yoshie Iizuka; Qing Yang; Courtney Coombes; Mark McClellan; Vijayalakshmi Shridhar; Edith Emmings; Mihir Shetty; Liqiang Chen; Teng Ai; Joyce Meints; Michael K Lee; Melissa Gardner; Martina Bazzaro
Journal:  Mol Cancer Res       Date:  2018-10-15       Impact factor: 5.852

6.  Quantitative Proteomic and Phosphoproteomic Comparison of 2D and 3D Colon Cancer Cell Culture Models.

Authors:  Xiaoshan Yue; Jessica K Lukowski; Eric M Weaver; Susan B Skube; Amanda B Hummon
Journal:  J Proteome Res       Date:  2016-10-10       Impact factor: 4.466

Review 7.  Microfluidic models for adoptive cell-mediated cancer immunotherapies.

Authors:  Giulia Adriani; Andrea Pavesi; Anthony T Tan; Antonio Bertoletti; Jean Paul Thiery; Roger D Kamm
Journal:  Drug Discov Today       Date:  2016-05-13       Impact factor: 7.851

8.  Self-Renewal and CSCs In Vitro Enrichment: Growth as Floating Spheres.

Authors:  Pooja Mehta; Caymen Novak; Shreya Raghavan; Maria Ward; Geeta Mehta
Journal:  Methods Mol Biol       Date:  2018

9.  Boyden chamber-based compartmentalized tumor spheroid culture system to implement localized anticancer drug treatment.

Authors:  Shohei Kaneda; Jiro Kawada; Marie Shinohara; Momoko Kumemura; Ryohei Ueno; Tomoaki Kawamoto; Kenji Suzuki; Beomjoon Kim; Yoshiho Ikeuchi; Yasuyuki Sakai; Dominique Collard; Hiroyuki Fujita; Teruo Fujii
Journal:  Biomicrofluidics       Date:  2019-10-24       Impact factor: 2.800

10.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.